BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8271053)

  • 1. Samarium-153-EDTMP dosimetry.
    Heggie JC
    J Nucl Med; 1994 Jan; 35(1):191-2. PubMed ID: 8271053
    [No Abstract]   [Full Text] [Related]  

  • 2. Samarium-153-EDTMP biodistribution and dosimetry estimation.
    Eary JF; Collins C; Stabin M; Vernon C; Petersdorf S; Baker M; Hartnett S; Ferency S; Addison SJ; Appelbaum F
    J Nucl Med; 1993 Jul; 34(7):1031-6. PubMed ID: 7686217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ESR dosimetry of 89Sr and 153Sm in bone.
    Kinoshita A; Braga FJ; Graeff CF; Baffa O
    Appl Radiat Isot; 2001 Feb; 54(2):269-74. PubMed ID: 11200888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Inhibitory effect of samarium-153-labeled ethylenediaminetetramethylene phosphonate (EDTMP) on bone invasion and osteolysis in Walker 256 carcinoma bearing rats].
    Shi B; Fu Z; Lei XH
    Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):423-6. PubMed ID: 10920873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 153 Samarium-EDTMP in myeloablative dosage followed by a second autotransplantation in patients with relapsed multiple myeloma.
    Knop S; Dohmen BM; Kanz L; Bares R; Einsele H
    Haematologica; 2004 Sep; 89(9):ECR36. PubMed ID: 15377488
    [No Abstract]   [Full Text] [Related]  

  • 6. Samarium-153 EDTMP therapy of disseminated skeletal metastasis.
    Turner JH; Martindale AA; Sorby P; Hetherington EL; Fleay RF; Hoffman RF; Claringbold PG
    Eur J Nucl Med; 1989; 15(12):784-95. PubMed ID: 2483138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases.
    Bayouth JE; Macey DJ; Kasi LP; Fossella FV
    J Nucl Med; 1994 Jan; 35(1):63-9. PubMed ID: 7505819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pronounced therapeutic effect of samarium 153-ethylenediaminetetramethylene phosphonate in an orthotopic human osteosarcoma tibial tumor model.
    Winderen M; Kjønniksen I; Fodstad O
    J Natl Cancer Inst; 1995 Feb; 87(3):221-2. PubMed ID: 7707409
    [No Abstract]   [Full Text] [Related]  

  • 9. Estimated human absorbed dose of a new (153)Sm bone seeking agent based on biodistribution data in mice: Comparison with (153)Sm-EDTMP.
    Yousefnia H; Zolghadri S
    Phys Med; 2015 Nov; 31(7):714-9. PubMed ID: 26095757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Samarium-153 lexidronam for painful bone metastases.
    Med Lett Drugs Ther; 1997 Aug; 39(1008):83-4. PubMed ID: 9286284
    [No Abstract]   [Full Text] [Related]  

  • 11. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.
    Turner JH; Claringbold PG; Hetherington EL; Sorby P; Martindale AA
    J Clin Oncol; 1989 Dec; 7(12):1926-31. PubMed ID: 2585026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Samarium-153-EDTMP for palliation of ankylosing spondylitis, Paget's disease and rheumatoid arthritis.
    Alberts AS; Brighton SW; Kempff P; Louw WK; Beek AV; Kritzinger V; Westerink HP; van Rensburg AJ
    J Nucl Med; 1995 Aug; 36(8):1417-20. PubMed ID: 7543145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation dose calculations in persons receiving injection of samarium-153 EDTMP.
    Logan KW; Volkert WA; Holmes RA
    J Nucl Med; 1987 Apr; 28(4):505-9. PubMed ID: 3572536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen.
    Kennedy GA; Durrant S; Butler J; Morton J; Western R; Bartlett ML; Allison R; MacFarlane DJ
    Leukemia; 2005 May; 19(5):879-80. PubMed ID: 15759033
    [No Abstract]   [Full Text] [Related]  

  • 15. The importance of BMI in dosimetry of
    Fallahpoor M; Abbasi M; Asghar Parach A; Kalantari F
    Appl Radiat Isot; 2017 Jun; 124():1-6. PubMed ID: 28284122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [153Sm-EDTMP for moderate and severe bone cancer pain].
    Deng H; Luo S; Tan T; Mo T; Liang Z; Pu M; Jiao J; Zhong S; Wang Q; Hu Y
    Hua Xi Yi Ke Da Xue Xue Bao; 1995 Dec; 26(4):391-4. PubMed ID: 8732058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The value of Sm-153-EDTMP for treatment of metastatic bone pain and improving quality of life].
    Jiang CY; Zhu BL; Zhang YJ
    Zhonghua Zhong Liu Za Zhi; 1994 Mar; 16(2):118-21. PubMed ID: 7523052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of 153Sm-EDTMP on hematopoiesis and vital organs of 93 patients with bone tumor].
    Deng H; Tan T; Mo T; Zhong S; Kuan A; Hu Y
    Hua Xi Yi Ke Da Xue Xue Bao; 1995 Jun; 26(2):155-9. PubMed ID: 7490021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Samarium-153-EDTMP in bone metastases.
    Ahonen A; Joensuu H; Hiltunen J; Hannelin M; Heikkilä J; Jakobsson M; Jurvelin J; Kairemo K; Kumpulainen E; Kulmala J
    J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):123-7. PubMed ID: 7543288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma.
    Franzius C; Bielack S; Sciuk J; Vollet B; Jürgens H; Schober O
    Nuklearmedizin; 1999; 38(8):337-40. PubMed ID: 10615669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.